Price
No data yet.
Signal Score (90d)
100Aug 17Aug 17
Quote
Day Range
—
52-Week Range
—
Volume
—
Market Cap
—
50-Day Avg
—
200-Day Avg
—
Prev Close
—
Open
—
Valuation & Ratios
P/E Ratio
—
EPS
—
P/B Ratio
—
P/S Ratio
—
Debt/Equity
—
Current Ratio
—
Dividend Yield
—
Gross Margin
—
Returns & Efficiency
Return on Equity
—
Return on Assets
—
FCF Yield
—
EV/EBITDA
—
Social Signal Score
50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1
Valuation
RAD.AXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·6h ago·Neutral
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 meeting with the U. S. FDA scheduled for October 1st, 2026; on track to be Phase 3 ready by year-end 2026 SYDNEY and MALVERN, Pa.
View source ↗